Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.52 |
| ▸ | PDE4A | P27815 | 6/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | LHCGR | P22888 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025976 | 0.91 | BRAF (0.49) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5025998 | 0.85 | BRAF (0.46) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4902884 | 0.85 | BRAF (0.39) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4904202 | 0.82 | BRAF (0.61) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5025983 | 0.80 | BRAF (0.49) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6219075 | 0.79 | MEN1 (0.46) | IKBKBMEN1KMT2A | |
| SCHEMBL4419271 | 0.78 | LHCGR (0.53) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4907129 | 0.76 | BRAF (0.56) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6110243 | 0.75 | IKBKB (0.64) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4907258 | 0.75 | BRAF (0.41) | BRAFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| US-7317006-B2 | Thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-01-08 | — | — | US | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1427733-B1 | THIENO[2,3-D]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | ORGANON NV (NL) | 2006-11-15 | — | — | EP | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | BRAF 3/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | BRAF 4677/4885PDE4A 638/4885PDE4B 915/4885 |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | BRAF 4516/4885PDE4A 214/4885PDE4B 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.